Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
0.00 | 6.85M | 0.00 | 0.00 | 0.00 | Gross Profit |
0.00 | 6.85M | -130.92K | -33.99K | 0.00 | EBIT |
-201.06M | -171.28M | -212.26M | -139.31M | -10.44M | EBITDA |
-221.97M | -166.07M | -212.26M | -379.16M | -10.43M | Net Income Common Stockholders |
-235.76M | -151.09M | -216.21M | -381.85M | -11.04M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
482.18M | 256.55M | 393.64M | 595.08M | 7.23M | Total Assets |
576.80M | 360.25M | 444.31M | 629.63M | 11.72M | Total Debt |
117.23M | 84.59M | 69.80M | 75.70M | 5.63M | Net Debt |
-266.00M | -43.44M | -323.84M | -519.38M | -1.60M | Total Liabilities |
175.25M | 124.00M | 108.14M | 138.08M | 34.14M | Stockholders Equity |
401.55M | 236.24M | 336.17M | 491.55M | -22.42M |
Cash Flow | Free Cash Flow | |||
-142.09M | -160.51M | -201.68M | -136.33M | -10.63M | Operating Cash Flow |
-142.06M | -160.34M | -200.55M | -136.14M | -10.63M | Investing Cash Flow |
31.27M | -127.00M | -931.00K | 63.25M | 0.00 | Financing Cash Flow |
364.75M | 21.12M | 457.00K | 660.07M | 1.36M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
61 Neutral | $3.10B | ― | -32.17% | ― | -25.85% | -23.89% | |
61 Neutral | $1.94B | 3.04 | 60.26% | ― | 25.96% | ― | |
55 Neutral | $2.31B | ― | -24.67% | ― | 1436.97% | 68.03% | |
54 Neutral | $5.24B | 3.27 | -45.39% | 2.80% | 16.77% | -0.07% | |
53 Neutral | $1.90B | 21.22 | -6.25% | ― | ― | ― | |
45 Neutral | $1.72B | ― | -38.04% | ― | -82.38% | -164.76% | |
33 Underperform | $1.67B | ― | -74.29% | ― | -100.00% | -25.86% |
Centessa Pharmaceuticals announced updates on its OX2R agonist pipeline, including ORX750, ORX142, and ORX489, with significant clinical milestones anticipated in 2025. The company aims to position itself as a leader in the emerging category of OX2R agonist therapeutics, bolstered by a strong balance sheet and an estimated cash runway into mid-2027.